One of the well-studied examples is acute myeloid leukemia (AML), for which prognosis and treatment strategies depend on the detection of a wide spectrum of mutations: FLT3 internal tandem application (ITD), MLL partial tandem duplication (PTD), NPM1 insertion, CEBPA insertion/deletions (indels), and gene fusions PML-RARA, RUNX1-RUNX1T and CBFB-MYH11, among others [5]. This evidence concerns the gene CEBPA and acute myeloid leukemia.